The combination of carboplatin and topotecan in platinum-sensitive relapsed ovarian cancer could not improve progression-free survival or overall survival compared with established standard regimens.
from Cancer via ola Kala on Inoreader http://ift.tt/2dR4jbT
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου